by Anis Fahandej-Sadi | Dec 5, 2024
If you’re reading this, you’re probably aware of the massive strides the cell and gene therapy (CGT) industry has made in the last few years. Between 2017 and 2022, six CGT products were approved by the U.S. Food and Drug Administration, but we saw eight approvals in...
by Laya Kiani | Jul 11, 2024
Intellectual property (IP) rights in regenerative medicine (RM) are crucial for sparking innovation and staying ahead in a competitive market. Protecting inventions through patents and other IP rights encourages investment by giving inventors exclusive market rights....
by Laine Bodnar | Feb 29, 2024
In my role as a communication professional at CCRM, I have had the opportunity to attend industry conferences and events. There, I have met brilliant minds in the regenerative medicine and cell therapy field and learned about the work that’s happening in their...
by Krystal Jacques | Jan 10, 2024
The Second World War (WWII) and post WWII saw an appetite for new technology and science. In particular, after WWII scientists were encouraged to conduct research for the sake of knowledge and to benefit society. However, there weren’t as many opportunities outside of...
Comments